CI Investments Inc. Sells 3,764 Shares of Waters Corporation $WAT

CI Investments Inc. trimmed its position in Waters Corporation (NYSE:WAT) by 48.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,009 shares of the medical instruments supplier’s stock after selling 3,764 shares during the period. CI Investments Inc.’s holdings in Waters were worth $1,202,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in WAT. Integrated Wealth Concepts LLC boosted its position in shares of Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after purchasing an additional 30 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Waters by 5.9% in the third quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock valued at $189,000 after buying an additional 35 shares during the last quarter. Penserra Capital Management LLC grew its stake in shares of Waters by 13.1% during the second quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 38 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Waters by 1.8% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock valued at $679,000 after acquiring an additional 41 shares in the last quarter. Finally, Clearstead Advisors LLC raised its position in shares of Waters by 7.5% in the 3rd quarter. Clearstead Advisors LLC now owns 586 shares of the medical instruments supplier’s stock valued at $176,000 after purchasing an additional 41 shares during the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on WAT. Citigroup started coverage on shares of Waters in a research report on Tuesday, February 10th. They set a “buy” rating and a $425.00 target price on the stock. Robert W. Baird set a $363.00 price objective on shares of Waters in a report on Tuesday, February 10th. Bank of America reduced their target price on Waters from $410.00 to $350.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Barclays began coverage on Waters in a research note on Tuesday, February 10th. They set an “overweight” rating and a $400.00 price target on the stock. Finally, Wolfe Research raised Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 price objective on the stock in a report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $393.84.

Waters Stock Performance

NYSE WAT opened at $316.39 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.27 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $31.04 billion, a price-to-earnings ratio of 29.38, a PEG ratio of 2.20 and a beta of 1.20. The stock has a 50-day moving average of $363.12 and a 200 day moving average of $350.80. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $414.15.

Waters (NYSE:WAT) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. The firm had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. Waters had a return on equity of 34.79% and a net margin of 20.30%.The business’s revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the firm posted $4.10 EPS. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Sell-side analysts anticipate that Waters Corporation will post 12.86 EPS for the current fiscal year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.